Infectious Diseases

A 10-year King County study found MMRV was the first vaccine for 15% of children, disproportionately Hispanic, Black, or VFC-eligible.

A matched cohort study found no meaningful difference in serious or outpatient infection risk between infliximab and adalimumab in pediatric IBD.

FDA approved the first generic rifapentine for active and latent tuberculosis, expanding treatment options for eligible pediatric patients.

Baloxavir marboxil is a first-in-class cap-dependent endonuclease inhibitor that functions as a prodrug.

The approval is based on data from the phase 3 STRIDE-13 trial.

A CHOP-led study identified IL-6 and IFN-γ immune activation tied to worse recovery in children with sepsis or organ failure.

The FDA has approved expanded indications for tocilizumab-bavi (TOFIDENCE), adding severe or life-threatening CAR T-cell–induced CRS and hospitalized COVID-19 in patients aged 2 years and older.

New research using a natural experiment design found consistent reductions in diagnosed influenza among vaccinated young children in every season studied from 2016 to 2023.

Common pediatric skin infections are often managed in primary care, but some presentations require dermatology referral and further evaluation.

FDA approved ensitrelvir for COVID-19 post-exposure prophylaxis in patients aged 12 years and older after positive phase 3 trial results.

French data suggest dual RSV immunization with RSVpreF and nirsevimab was associated with low infant RSV hospitalization rates.

National pediatric and infectious disease groups convened a measles summit as US cases reached the highest level in 35 years.

Modeling data suggest removing universal hepatitis B birth-dose vaccination could increase neonatal and chronic HBV infections in US infants.

Raising pediatric flu vaccination to 70% could significantly reduce outpatient visits, hospitalizations, and deaths, easing strain on US systems.

Maternal RSV vaccination and nirsevimab were linked to lower infection rates and reduced severity in infants younger than 6 months.

MMR coverage remained below herd immunity 20 months after an Ohio outbreak, with minimal gains and persistent disparities in children.

An analysis found nirsevimab was associated with substantial reductions in RSV-related hospitalizations among preterm infants and those with congenital heart disease.

Combined use of nirsevimab and maternal RSV vaccination was associated with a 43% reduction in RSV-related hospitalizations and ED visits among infants.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

New data reveal that implementing rapid diagnostic testing for RSV reduces the rate of unnecessary antibiotic prescriptions for viral respiratory infections.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Trial data indicate that clesrovimab has a safety profile comparable to palivizumab and maintained protection against RSV-related infections.

A study found that a nirsevimab immunization program reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second.

Whole-genome sequencing revealed extensive NICU transmission of MSSA and MRSA strains linked to invasive infection.

The AAP released its 2026 childhood immunization schedule, maintaining evidence-based vaccine recommendations and expanding guidance across routine, catch-up, and risk-based care.